Applied Finance Capital Management LLC Sells 8,524 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Applied Finance Capital Management LLC reduced its stake in Regeneron Pharmaceuticals by 30.1%, selling 8,524 shares and holding 19,793 shares worth $12,553,000 at the end of the reporting period.
• Analysts have issued mixed ratings for Regeneron, with a consensus rating of "Moderate Buy" and an average price target of $837.61.
• Regeneron reported quarterly earnings of $8.22 EPS, missing expectations, with revenue of $3.03 billion compared to estimates of $3.40 billion, marking a 3.7% decline year-over-year.

Applied Finance Capital Management LLC reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 30.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 19,793 shares of the biopharmaceutical company's stock after selling 8,524 shares during the quarter. Applied Finance Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $12,553,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. Pinney & Scofield Inc. acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. raised its stake in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 31 shares during the period. Tompkins Financial Corp acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $32,000. Curat Global LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $32,000. Finally, American National Bank & Trust acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $44,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $2.26 during trading hours on Wednesday, hitting $560.41. The stock had a trading volume of 203,812 shares, compared to its average volume of 1,111,524. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The stock's 50-day moving average price is $540.67 and its two-hundred day moving average price is $606.53. The stock has a market capitalization of $60.50 billion, a price-to-earnings ratio of 14.27, a PEG ratio of 2.10 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same period last year, the firm posted $9.55 earnings per share. The company's revenue for the quarter was down 3.7% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.63%. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Analysts Set New Price Targets

Several analysts have recently commented on REGN shares. Guggenheim reissued a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and lowered their price objective for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. BMO Capital Markets decreased their price target on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a research report on Monday, June 2nd. Robert W. Baird decreased their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research report on Friday, April 25th. Finally, The Goldman Sachs Group decreased their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $837.61.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.